President and chief executive, Shionogi Inc.
Appears in 1 story
Will lead integration of IntraBio as a subsidiary
Shionogi agreed to pay $2 billion for IntraBio, a Texas biotech whose single marketed drug treats two inherited neurological disorders. The deal, announced October 5, hands the Osaka-based drugmaker a product that weeks earlier became the first approved treatment for ataxia-telangiectasia, a rare and fatal genetic disease.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
